Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 01 Feb 2023 Results of post hoc analysis from 6 studies(n=209 from NCT01859988, NCT02277743, NCT02277769, NCT03054428, NCT02260986, NCT02755649) assessing Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis published in the JAMA Dermatology
- 03 Dec 2021 Results comparing (n=2932) hospitalization rates (all-cause and AD-related) of adults with atopic dermatitis treated with dupilumab versus control by post hoc analysis of 7 RCTs (NCT01548404, NCT02277743, NCT02277769, NCT01859988, NCTO2210780, NCT02755649 and NCT02260986), presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 Sep 2019 Results (n=250) of sub-analysis of three studies (AD-1021; LIBERTY AD SOLO 1 and LIBERTY AD CHRONOS) assessing efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis, published in the British Journal of Dermatology.